000292488 001__ 292488
000292488 005__ 20250127163445.0
000292488 0247_ $$2doi$$a10.1093/neuonc/noae176
000292488 0247_ $$2pmid$$apmid:39215664
000292488 0247_ $$2ISSN$$a1522-8517
000292488 0247_ $$2ISSN$$a1523-5866
000292488 0247_ $$2altmetric$$aaltmetric:168926182
000292488 037__ $$aDKFZ-2024-01735
000292488 041__ $$aEnglish
000292488 082__ $$a610
000292488 1001_ $$0P:(DE-HGF)0$$aHoa Ho, Kim$$b0$$eFirst author
000292488 245__ $$aActivation of Wnt/β-catenin signaling is critical for the tumorigenesis of choroid plexus.
000292488 260__ $$aOxford$$bOxford Univ. Press$$c2025
000292488 3367_ $$2DRIVER$$aarticle
000292488 3367_ $$2DataCite$$aOutput Types/Journal article
000292488 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737971006_25370
000292488 3367_ $$2BibTeX$$aARTICLE
000292488 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000292488 3367_ $$00$$2EndNote$$aJournal Article
000292488 500__ $$a#EA:A320#LA:A320#  / DKFZ/ZMBH Alliance / 2025 Jan 12;27(1):106-122
000292488 520__ $$aChoroid plexus (ChP) is the secretory epithelial structure located in brain ventricles. Choroid plexus tumors (CPTs) are rare neoplasms predominantly occurring in young patients with intensified malignancy in children. CPT treatment is hindered by insufficient knowledge of the tumor pathology and limited availability of valid models.Genomic and transcriptomic data from CPT patients were analyzed to identify the putative pathological pathway. Cellular and molecular techniques were employed to validate bioinformatic results in CPT patient samples. Pharmacologic inhibition of Wnt/β-catenin signaling was assessed in CPT cells. Cell-based assays of ChP cell lines were performed following CRISPR-Cas9-derived knockout and over-expression of Wnt/β-catenin pathway genes. 3D CPT model was generated through CRISPR-Cas9-derived knockout of APC.We discovered that Wnt/β-catenin signaling is activated in human CPTs, likely as a consequence of large-scale chromosomal instability events of the CPT genomes. We demonstrated that CPT-derived cells depend on autocrine Wnt/β-catenin signaling for survival. Constitutive Wnt/β-catenin pathway activation, either through knock-out of the negative regulator APC or overexpression of the ligand WNT3A, induced tumorigenic properties in ChP 2D in vitro models. Increased activation of Wnt/β-catenin pathway in ChP organoids, through treatment with a potent GSK3β inhibitor, reduced the differentiation of mature ChP epithelia cells. Remarkably, the depletion of APC was sufficient to induce the oncogenic transformation of ChP organoids.Our research identifies Wnt/β-catenin signaling as a critical driver of CPT tumorigenesis and provides the first 3D in vitro model for future pathological and therapeutic studies of CPT.
000292488 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000292488 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000292488 650_7 $$2Other$$aAPC
000292488 650_7 $$2Other$$aBrain tumor
000292488 650_7 $$2Other$$aWnt signaling
000292488 650_7 $$2Other$$achoroid plexus organoid
000292488 650_7 $$2Other$$arare childhood cancer
000292488 7001_ $$0P:(DE-He78)7febcb2f4385ed4b379f34d11954e8e7$$aTrapp, Marleen$$b1$$udkfz
000292488 7001_ $$0P:(DE-He78)38a36539566d2f585597c49d5ee70c64$$aGuida, Catello$$b2$$udkfz
000292488 7001_ $$0P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2$$aIvanova, Ekaterina$$b3
000292488 7001_ $$aDe Jaime-Soguero, Anchel$$b4
000292488 7001_ $$0P:(DE-HGF)0$$aJabali, Ammar$$b5
000292488 7001_ $$aThomas, Christian$$b6
000292488 7001_ $$aSalasova, Alena$$b7
000292488 7001_ $$aBernatík, Ondřej$$b8
000292488 7001_ $$aSalio, Chiara$$b9
000292488 7001_ $$0P:(DE-HGF)0$$aHorschitz, Sandra$$b10
000292488 7001_ $$aHasselblatt, Martin$$b11
000292488 7001_ $$aSassoe-Pognetto, Marco$$b12
000292488 7001_ $$aČajánek, Lukáš$$b13
000292488 7001_ $$aIshikawa, Hiroshi$$b14
000292488 7001_ $$aSchroten, Horst$$b15
000292488 7001_ $$aSchwerk, Christian$$b16
000292488 7001_ $$aAcebrón, Sergio P$$b17
000292488 7001_ $$0P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aAngel, Peter$$b18$$udkfz
000292488 7001_ $$0P:(DE-He78)7622d683a69f6d26d04f928d1b15d64b$$aKoch, Philipp$$b19
000292488 7001_ $$0P:(DE-He78)7de884e25564c58f26d5c8dbed578256$$aPatrizi, Annarita$$b20$$eLast author$$udkfz
000292488 773__ $$0PERI:(DE-600)2094060-9$$a10.1093/neuonc/noae176$$gp. noae176$$n1$$p106-122$$tNeuro-Oncology$$v27$$x1522-8517$$y2025
000292488 8767_ $$8SOA24LT010027$$92024-08-30$$d2024-11-14$$eAPC$$jZahlung erfolgt
000292488 909CO $$ooai:inrepo02.dkfz.de:292488$$pVDB$$pOpenAPC$$popenCost
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7febcb2f4385ed4b379f34d11954e8e7$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)38a36539566d2f585597c49d5ee70c64$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)64b69fa0317d5a02bd67528ceef097c2$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f4f068e71e0d87bf0ad51e6214ab84e9$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7622d683a69f6d26d04f928d1b15d64b$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000292488 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7de884e25564c58f26d5c8dbed578256$$aDeutsches Krebsforschungszentrum$$b20$$kDKFZ
000292488 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000292488 9141_ $$y2024
000292488 915pc $$0PC:(DE-HGF)0000$$2APC$$aAPC keys set
000292488 915pc $$0PC:(DE-HGF)0001$$2APC$$aLocal Funding
000292488 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2023-10-24$$wger
000292488 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-24
000292488 915__ $$0StatID:(DE-HGF)9915$$2StatID$$aIF >= 15$$bNEURO-ONCOLOGY : 2022$$d2023-10-24
000292488 9202_ $$0I:(DE-He78)A320-20160331$$kA320$$lA320 NWG Neuronal signaling and morphogenesis$$x0
000292488 9201_ $$0I:(DE-He78)A320-20160331$$kA320$$lA320 NWG Neuronal signaling and morphogenesis$$x0
000292488 9201_ $$0I:(DE-He78)A340-20160331$$kA340$$lA340 NWG Engeneering von Zellidentitäten und Krankheitsmodellen$$x1
000292488 9201_ $$0I:(DE-He78)A100-20160331$$kA100$$lA100 Signaltransduktion/ Wachstumskontrolle$$x2
000292488 9200_ $$0I:(DE-He78)A320-20160331$$kA320$$lA320 NWG Neuronal signaling and morphogenesis$$x0
000292488 980__ $$ajournal
000292488 980__ $$aVDB
000292488 980__ $$aI:(DE-He78)A320-20160331
000292488 980__ $$aI:(DE-He78)A340-20160331
000292488 980__ $$aI:(DE-He78)A100-20160331
000292488 980__ $$aAPC
000292488 980__ $$aUNRESTRICTED
000292488 9801_ $$aAPC